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Increased Thromboxane Biosynthesis Is Associated
With Poststroke Dementia
F. van Kooten, MD; G. Ciabattoni, MD; P.J. Koudstaal, MD; D.E. Grobbee, MD;
C. Kluft, PhD; C. Patrono, MD
Background and Purpose—It has been suggested that daily intake of aspirin is associated with a reduction of cognitive
decline, both in normal and in demented subjects, but the mechanism is unclear. We have therefore studied the
relationship between thromboxane (TX) A2 biosynthesis, as reflected by the urinary excretion of 11-dehydro-TXB2, and
the presence of dementia in patients after acute stroke.
Methods—Patients from the Rotterdam Stroke Databank were screened for dementia between 3 and 9 months after stroke.
Patients had a full neurological examination, neuropsychological screening, and, if indicated, extensive neuropsycho-
logical examination. Criteria used for the diagnosis of dementia were from the Diagnostic and Statistical Manual of
Mental Disorders, Third Edition (Revised). Urine samples were taken at the time of screening. Urinary 11-dehydro-
TXB2 was measured by means of a previously validated radioimmunoassay.
Results—Dementia was diagnosed in 71 patients, and urine samples were available for 62. Median value (range) of
11-dehydro-TXB2 was 399 (89 to 2105) pmol/mmol creatinine for demented patients versus 273 (80 to 1957) for 69
controls with stroke but without dementia (P50.013). No difference was found between 44 patients with vascular
dementia, 404 (89 to 2105) pmol/mmol creatinine, and 18 patients with Alzheimer’s disease plus cerebrovascular
disease, 399 (96 to 1467) pmol/mmol creatinine (P50.68). In a stepwise logistic regression analysis, in which possible
confounders such as use of antiplatelet medication, cardiovascular risk factors, and type of stroke were taken into
account, increased urinary excretion of 11-dehydro-TXB2 remained independently related to the presence of dementia
(OR 1.12, 95% CI 1.03 to 1.22 per 100 pmol/mmol creatinine). The difference in metabolite excretion rates between
demented and nondemented patients was most prominent within the subgroup of ischemic stroke patients who received
aspirin (P,0.01).
Conclusions—Increased thromboxane biosynthesis in the chronic phase after stroke is associated with the presence of but
not the type of poststroke dementia. It is particularly apparent in patients on aspirin, thereby suggesting the involvement
of extraplatelet sources of TXA2 production in this setting. (Stroke. 1999;30:1542-1547.)
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Dementia is one of the most important causes of disability inthe elderly. The increased aging of the population calls for
strategies that reduce both the occurrence and severity of
dementia in order to lighten the burden on society in terms of
health care, disability, and hospital and institutional care. It has
been estimated that in 10% to 40% of all demented patients,
vascular lesions or thromboembolic processes represent the
identifiable cause of dementia.1 Several studies2–7 have ad-
dressed the hypothesis that aspirin might have a beneficial effect
on the occurrence and progression of dementia and on cognitive
function in general. In one randomized trial, patients with
multi-infarct dementia benefited from aspirin therapy, with
improvement of cognitive performance scores and cerebral
perfusion values.2 This study, however, was not placebo con-
trolled. In another trial, subjects at high risk for cardiovascular
disease showed better cognitive performance after 5 years of
treatment with antithrombotic therapy (ie, aspirin, warfarin, or
both) than those treated with placebo.5 The effect, however, was
small, and the patients studied represented a subgroup from a
trial that was designed for another purpose. In 2 nonrandomized,
population-based studies, either no effect of aspirin on cognitive
function was found at all6,7 or a small, not statistically signifi-
cant, positive effect was reported.4 Finally, a positive effect on
cognitive performance of NSAIDs or aspirin was reported in
patients diagnosed with possible or probable Alzheimer’s
disease.3
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These studies suggest a positive effect of aspirin treatment
on cognitive performance, in both demented patients and
otherwise healthy elderly subjects. The evidence, however, is
scarce; the effect, if any, is modest; and the underlying
mechanisms are largely unknown. Aspirin may be beneficial
through its antiplatelet effect,8 by preventing recurrent cere-
bral infarcts, or through its anti-inflammatory properties. The
dose requirement for the apparent beneficial effect of aspirin
on cognitive performance would favor the antiplatelet effect
as the most likely explanation. In a previous study, we
reported an association between platelet activation, as re-
flected by thromboxane metabolite excretion, in the acute
phase of stroke and stroke severity.9 There was also a
nonsignificant trend for enhanced platelet activation in pa-
tients with the worst 3-month outcome as measured on the
Rankin scale, a handicap scale that reflects the degree of
independence of the patient, taking cognitive performance
into account.
In this study, we have prospectively investigated the
relationship between in vivo thromboxane biosynthesis dur-
ing the chronic phase after stroke and the presence of
poststroke dementia.
Subjects and Methods
Study Patients
Patients were recruited from the Rotterdam Stroke Databank, a
prospective registry of patients with transient ischemic attack (TIA),
ischemic stroke, or a primary intracerebral hemorrhage, admitted to
the department of Neurology of the Dijkzigt University Hospital
Rotterdam in the Netherlands. From March 1, 1993 until January 15,
1996, 825 consecutive patients were entered into this registry, of
whom 300 met the entry criteria for the Dutch Vascular Factors in
Dementia Study.10 Patients had to be 55 years or older, and they had
to be admitted to our neurology ward with a TIA, cerebral infarction
or intracerebral hemorrhage. Reasons for exclusion were, in short, as
follows: 24% were too young, 15% died within 3 months after
stroke, 6% did not give consent, 5% had had a TIA and no
neurological signs on examination, 4% moved out of the region, 5%
were untestable because of severe aphasia, 2% were not native Dutch
speakers, and 3% were excluded for various other reasons. Of the
remaining 300 patients, 71 were demented, and in 62 of these urinary
samples were available for thromboxane metabolite measurements.
Seventy-one control patients, including patients with TIA, ischemic
stroke, and intracerebral hemorrhage, who were frequency matched
for age and sex, were randomly taken from the 229 nondemented
stroke and TIA patients. Urinary samples were available from 69 of
the 71 control subjects. All patients were screened according to a
strict protocol consisting of a full neurological examination, stan-
dardized blood tests, at least 1 and usually 2 CT scans of the brain,
duplex scanning of the carotid arteries, and a cardiological analysis
that included standard 12-lead ECG and, if indicated, 24-hour ECG
monitoring and echocardiography. The nature and time course of the
symptoms were recorded by means of a detailed checklist.11 Patients
with a cerebral infarction were further subdivided according to a
clinical classification: Total anterior circulation stroke, partial ante-
rior circulation stroke, lacunar stroke, and posterior circulation
stroke.12 Apart from the neurological history, the following vascular
risk factors were recorded: smoking habits, hypercholesterolemia
(history of hypercholesterolemia and/or fasting total cholesterol level
.6.5 mmol/L),13 hypertension (history of hypertension and/or sys-
tolic blood pressure .160 mm Hg and/or diastolic blood pressure
.90 mm Hg, treated or not), diabetes mellitus (history of diabetes
mellitus type I or II and/or a random blood glucose of 8 mmol/L
together with an HbA1c level of 6.30% or more, treated or not),14
atrial fibrillation (history of atrial fibrillation and/or atrial fibrillation
on ECG), and a history of intermittent claudication, angina pectoris,
prior myocardial infarction, retinal infarction, or stroke. We recorded
the medication, especially antiplatelet and anticoagulant treatment,
taken by the patients at the time of urinary sampling, which was
between 3 and 9 months after the onset of stroke. As customary in
the Netherlands, the vast majority of patients in our study were
treated with a dose of 30 mg of aspirin daily. Only patients with a
cardiac indication for aspirin (n516) were treated with a higher dose,
varying between 80 and 100 mg daily. Nine patients used NSAIDs
on a regular but not daily basis. Eight of these 9 were also using
aspirin, and only 1 used NSAIDs and no aspirin. In the analysis, this
patient was grouped in the nonaspirin group.
Five patients with cerebral ischemia as qualifying event were not
treated with antithrombotic medication at the time of assessment.
One of them had a thrombocytopenia, which prevented aspirin
treatment; the other 4 had recurrent systemic bleedings (3 had gastric
bleeding and 1 recurrent urinary tract bleeding). On the other hand,
5 patients with an intracerebral hemorrhage as qualifying event
received antithrombotic treatment at the time of assessment, because
they already had an indication for antithrombotic treatment before
their hemorrhage. In 1 patient, oral anticoagulant treatment was
restarted in the chronic phase after the bleeding because of a
prosthetic aortic valve. In 2 patients with atrial fibrillation, 1 with a
history of TIA and 1 a history of recurrent myocardial infarction,
aspirin was started in the chronic phase after oral anticoagulant
treatment was stopped in the acute phase of the hemorrhage. In 2
patients with a history of TIA, aspirin was restarted in the chronic
phase.
Assessment of Cognitive Function and Dementia
Premorbid cognitive function was assessed by means of an interview
with a close informant and the score on the Blessed Dementia
Scale.15 Cognitive function was assessed through a neurological
examination and by a series of neuropsychological screening instru-
ments between 3 and 9 months after onset of stroke. We performed
the Mini-Mental State Examination (MMSE),16 Geriatric Mental
Status organic scale,17 and the Dutch version of the cognitive and
self contained part of the Cambridge Examination for Mental
Disorders of the Elderly, the CAMCOG.18 In patients in whom
dementia was clinically suspected, extensive neuropsychological
evaluation was performed. Based on information from a close
relative, the results of extensive neuropsychological evaluation, and
the clinical impression on examination, the diagnosis of dementia
was assessed by a diagnostic panel that consisted of a neuropsychol-
ogist, 2 neurologists, and a physician of the Rotterdam Stroke
Databank. For the diagnosis of dementia, the DSM-III-R criteria19
were applied. The NINDS-AIREN research criteria20 were used to
distinguish between patients with vascular dementia and those with
Alzheimer’s disease plus cerebrovascular disease. The latter were
patients with progressive cognitive deterioration existing before the
onset of stroke, without a history or signs of cerebrovascular disease
until the present stroke occurred, thus fulfilling the clinical criteria
for possible Alzheimer’s disease.21 The degree of handicap was also
assessed between 3 and 9 months after onset of stroke by means of
the modified Rankin scale.22
Measurements of Thromboxane Biosynthesis
Urine samples were collected 3 to 9 months after stroke, thus
avoiding short-term fluctuations in thromboxane biosynthesis related
to the acute phase of stroke.9,23 The creatinine concentration was
measured, and samples of 50 mL were immediately frozen and
stored at 220°C until extraction. Analytical measurements of 11-
dehydro-TXB2, a major enzymatic metabolite of TXB2 in humans,
were performed with blinding to the diagnosis of dementia. Immu-
noreactive 11-dehydro-TXB2 was extracted from 10-mL aliquots of
each coded urine sample (the pH was adjusted to 4.0 with formic
acid) on SEP-PAK C18 cartridges (Waters Associates) and eluted
with ethyl acetate. The eluates were subjected to silicic acid column
chromatography and further eluted with benzene/ethyl acetate/meth-
anol (60:40:30, vol/vol). Immunoreactive 11-dehydro-TXB2 eluted
from silicic acid columns was assayed at a final dilution of 1:30 to
van Kooten et al Increased Thromboxane Biosynthesis and Poststroke Dementia 1543
1:1000, as described previously.24 The urinary excretion rate of
11-dehydro-TXB2 was expressed as picomoles per millimole of
creatinine.
Statistical Analysis
Data were analyzed by means of the Statistical Package for the
Social Sciences (SPSS Inc) and Egret statistical software. Values of
11-dehydro-TXB2 between groups were compared with the Mann-
Whitney U test. Differences in baseline characteristics between
demented and nondemented patients were compared with use of the
Student t test, x2 test, and Fisher exact test where appropriate. Values
of P,0.05 (2-sided testing) were considered statistically significant.
A logistic regression analysis, in which potential confounders such
as age, gender, use of antiplatelet medication, cardiovascular risk
factors (hypertension, hypercholesterolemia, atrial fibrillation, smok-
ing habit), and type and site and of stroke were taken into account,
was performed to investigate whether 11-dehydro-TXB2 was inde-
pendently related to the presence of dementia.
Results
Dementia was diagnosed in 71 (23.7%) of the 300 stroke
patients. Three (6.5%), 54 (25%), and 14 (39%) of the
patients with TIA, ischemic stroke, and intracerebral hemor-
rhage, respectively, were demented. Patients with an intrace-
rebral hemorrhage had a higher risk of dementia (OR 2.31,
95% CI 1.04 to 5.08) and patients with TIA a lower risk (OR
0.19, 95% CI 0.06 to 0.67). The mean age of the demented
patients was 73.367.7 years and that of the nondemented
patients 62.868.0 years (P,0.001). Of the demented pa-
tients, 52% were female compared with 37% of the controls
(P50.03).
Urine samples were available from 62 demented patients
and 69 controls. Table 1 shows the baseline characteristics in
relation to dementia for both groups. No statistically signifi-
cant differences in age, gender, type of stroke, and clinical
subtype of cerebral infarction existed between the 2 groups,
although patients with TIA were numerically more frequent
in the control group and more patients with intracerebral
hemorrhage were present in the group with dementia. Patients
who used neither oral anticoagulant nor antiplatelet medica-
tion were more frequent in the dementia group (P50.03).
However, no statistically significant difference existed be-
tween the 2 groups in the numbers of patients using aspirin or
anticoagulant medication.
Patients with dementia had a significantly higher 11-
dehydro-TXB2 excretion (median 399, range 89 to 2105
pmol/mmol creatinine) than nondemented patients, (median
273, range 80 to 1957, P50.01), as detailed in Table 2. No
difference in 11-dehydro-TXB2 excretion was found between
the 2 major types of dementia median 404, range 89 to 2105
pmol/mmol creatinine for vascular dementia and median 399,
range 96 to 1467 for Alzheimer’s disease plus cerebrovascu-
lar disease. Impaired performance on cognitive screening
tests was associated with increased 11-dehydro-TXB2 excre-
tion (P50.003 for the MMSE and P50.03 for the CAM-
COG). The correlation, however, between cognitive scores
and level of 11-dehydro-TXB2 was only modest: r250.10
(P,0.001) and r250.05 (P,0.001) for MMSE and CAM-
COG, respectively. Patients with severe strokes, defined as a
TABLE 1. Clinical Characteristics of Stroke Patients in Relation to the Presence
of Dementia
Characteristic n
Demented,
n (%)
Control,
n (%) P
Age, mean6SD, y 131 73.867.9 73.668.2 0.90
Gender
Male 69 29 (47) 40 (58) 0.20
Female 62 33 (53) 29 (42)
Type of stroke
TIA 12 3 (5) 9 (13) 0.10
Cerebral infarction 99 46 (74) 53 (77) 0.73
Intracerebral hemorrhage 20 13 (21) 7 (10) 0.09
Clinical subtype of cerebral infarction
TACS 11 7 (15) 4 (35) 0.22
PACS 46 20 (44) 26 (49) 0.58
LACS 30 11 (24) 19 (8) 0.20
POCS 12 8 (17) 4 (8) 0.13
Severity
Rankin score of #3 at follow-up 103 38 (61) 65 (94) ,0.001
Rankin score of .3 at follow-up 28 24 (39) 4 (6)
Antithrombotic medication
Aspirin 77 36 (58) 41 (59) 0.90
Oral anticoagulant 34 12 (19) 22 (32) 0.10
Neither aspirin nor oral anticoagulant 20 14 (23) 6 (9) 0.03
n indicates number of patients; TACS, total anterior circulation stroke; PACS, partial anterior
circulation stroke; LACS, lacunar stroke; and POCS, posterior circulation stroke.
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Rankin scale score of .3 at follow-up, had significantly
higher metabolite excretion levels than patients with minor
stroke (P50.0002). The group of patients treated with aspirin
had significant lower excretion levels of 11-dehydro-TXB2
than untreated patients (P,0.0001).
Because aspirin treatment has a major impact on urinary
11-dehydro-TXB2, by largely suppressing platelet TXA2 bio-
synthesis8 we investigated the relationship between metabo-
lite excretion and dementia both in the presence and in the
absence of aspirin therapy. To avoid an imbalance in the
subgroups, patients with an intracerebral hemorrhage were
excluded, because almost none of them used aspirin. The
Figure depicts the individual values, with and without aspirin,
of 11-dehydro-TXB2 for patients with cerebral ischemia.
Only in the aspirin group were 11-dehydro-TXB2 excretion
rates significantly higher in demented patients than in con-
trols (P50.01). When hemorrhagic stroke patients were
added, the results remained the same (P50.007). In patients
not on aspirin therapy, the median values were 494 (range
167 to 1957), and 431 (range 105 to 2105), for nondemented
and demented patients, respectively (P50.73). For the aspirin
group the corresponding values were 196 (range 80 to 631)
and 290 (range 89 to 1935), respectively (P50.01). Thus, in
patients who did not have dementia at follow-up, aspirin
treatment was associated with 60% lower rate of
thromboxane biosynthesis than in the absence of antiplatelet
therapy, and only 2 of 39 aspirin-treated subjects had metab-
olite excretion in excess of the median value of untreated
subjects. In contrast, in patients who were demented at
follow-up, aspirin treatment was associated with a 33% lower
rate of TXA2 biosynthesis, and 13 of 35 treated subjects had
metabolite excretion in excess of the median value of un-
treated subjects. However, no firm conclusions can be drawn
because of the relatively small numbers and the large
variability.
In the logistic regression analysis, increased urinary excre-
tion of 11-dehydro-TXB2 remained independently related to
the presence of dementia, with an OR of 1.12 (95% CI 1.03
to 1.22) per 100 pmol/mmol creatinine.
Discussion
The main finding of the present study is that patients with
poststroke dementia more often show increased thromboxane
biosynthesis than nondemented controls. Elevated levels of
circulating platelet microparticles have been described earlier
in a small study of patients with multi-infarct dementia.25
However, the interpretation of blood indexes of platelet
activation is hampered by sampling-related artifacts.26
Among other factors associated with increased 11-
dehydro-TXB2 in our univariate analysis were atrial fibrilla-
tion, unfavorable outcome, and absence of antiplatelet treat-
ment, which is consistent with the results of a previous study
in patients with acute ischemic stroke.9 Atrial fibrillation was
also identified as risk factor for dementia in a population-
based study27 as well as in a stroke population.28 However, in
a multiple logistic regression analysis in which these con-
founders were taken into account, increased urinary excretion
of 11-dehydro-TXB2 remained independently related to the
presence of dementia.
Increased thromboxane biosynthesis may also reflect se-
vere vascular disease, which may lead to dementia. However,
this seems unlikely in light of a recent study in patients with
peripheral arterial disease,29 which has clearly demonstrated
that vascular disease per se is not associated with enhanced
thromboxane biosynthesis.
Individual urinary 11-dehydro-TXB2 excretion rates depicted on
a logarithmic scale for demented and nondemented patients
with cerebral ischemia, as a function of aspirin therapy. The hor-
izontal bars represent median values for each subgroup of
patients.
TABLE 2. Median and Range of 11-Dehydro-TXB2 Excretion
Rates as a Function of Dementia, Cognitive Function, Severity
of Stroke, and Medication
Variable n 11-Dehydro-TXB2 P
Dementia
No 69 273 (80–1957)
0.01
Yes 62 399 (89–2105)
Type of dementia
Alzheimer’s disease with CVD 18 399 (96–1467) 0.04*
Vascular 44 404 (89–2105) 0.04*
Possible 4 396 (220–796) 0.23*
Probable 40 404 (89–2105) 0.06*
Cognitive function
MMSE #24 64 399 (89–2105)
0.003
MMSE .24 67 269 (80–1313)
CAMCOG #76 60 380 (89–2105)
0.03
CAMCOG .76 71 272 (80–1957)
Severity of stroke
Rankin score of #3 at
follow-up
103 286 (80–1313)
0.0002
Rankin score of .3 at
follow-up
28 635 (89–2105)
Antithrombotic medication
No oral anticoagulant or aspirin 20 610 (188–1467)
Aspirin 77 214 (80–1935) ,0.0001#
Oral anticoagulant 34 479 (105–2105) 0.44#
*Vs nondemented patients.
#Vs no oral anticoagulant or aspirin.
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The role of aspirin in our setting remains puzzling, because
the association between dementia and increased thromboxane
biosynthesis was most prominent in patients with aspirin
treatment. This may reflect the play of chance, because the
subgroup analysis included a small number of patients. On
the other hand, this finding may suggest that stroke patients
who show increased thromboxane biosynthesis that cannot be
completely suppressed by aspirin have an increased risk of
dementia. This might imply that patients with poststroke
dementia have an important aspirin-insensitive source of
thromboxane biosynthesis. The involvement of prostaglandin
H synthase-2 (cyclooxygenase [COX]-2) in producing the
substrate for thromboxane synthase within the context of an
ongoing inflammatory process in the brain would be compat-
ible with this working hypothesis. Among the cell types
endowed with thromboxane synthase and capable of express-
ing COX-2 in response to inflammatory cytokines and growth
factors are monocytes and macrophages.30 Moreover, trans-
cellular biosynthesis of TXA2 may occur through the bio-
chemical cooperation of cells expressing COX-2 (eg, vascular
endothelial cells) with aspirinated platelets.31 Aspirin is
considerably less potent in inhibiting human monocyte
COX-2 than platelet COX-1 activity.32 Thus, plasma aspirin
concentrations achieved at conventional antiplatelet dosage
are inadequate to suppress COX-2–dependent eicosanoid
biosynthesis. Cipollone et al32 have recently reported that in
unstable angina, episodes of aspirin-insensitive TXA2 biosyn-
thesis may reflect extraplatelet sources possibly expressing
COX-2 in response to a local inflammatory milieu. If the
same mechanism is operative in the setting of cerebral
ischemia and inflammation, this might explain the rather
conflicting results obtained with aspirin in observational
studies2,4,5 as well as the apparent protection against Alzhei-
mer’s disease associated with nonaspirin NSAIDs.3 These
drugs (eg, ibuprofen) are equally potent in inhibiting human
platelet COX-1 and monocyte COX-2.30
We conclude that (1) patients with poststroke dementia
more often show increased thromboxane biosynthesis than
nondemented stroke patients; (2) increased thromboxane
biosynthesis is not associated with the type of poststroke
dementia; and (3) the association between thromboxane
biosynthesis and the presence of poststroke dementia is
particularly apparent in patients on aspirin treatment, which
suggests that patients with poststroke dementia have an
aspirin-insensitive source of thromboxane biosynthesis, pos-
sibly related to COX-2 expression in the brain. The availabil-
ity of specific COX-2 inhibitors offers the opportunity to test
this hypothesis with a properly designed randomized trial.
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